Patient Condition
Early Huntington's disease, CAG repetition number 46, mild chore-like movement, normal and low cognitive function, MoCA score 25. UHDRS TMS 16 points, TFC 12 points. Selected into the stem cell combined gene silencing therapy trial.
Treatment Timeline
| Phase | Details | Date |
|---|
| Clinical trial screening and baseline assessment | | |
| MSC stem cell transplantation + gene silencing | | |
| Postoperative recovery + comprehensive rehabilitation | | |
| Follow-up assessment and maintenance rehabilitation | | |
Treatment Outcome
| before | UHDRS TMS 16, TFC 12, MoCA 25, mild choreo-like exercise, normal and low cognitive function |
|---|
| after | UHDRS TMS dropped to 9 points (7 points improvement), TFC increased to 13 points (1 point improvement), MoCA improved to 27 points, and motor symptoms were significantly reduced |
|---|
| highlight | The innovative stem cell combined with gene silencing treatment program is safe, and the dual mechanism of action significantly improves exercise function |
|---|